Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial

Journal Article · Wed Aug 15 00:00:00 EDT 2018 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2018.04.068· OSTI ID:23073254

Xu, Yongteng; Rong, Xiaoming ^[1]; Hu, Weihan ^[2]; Huang, Xiaolong; Li, Yi ^[1]; Zheng, Dong ^[3]; Cai, Zhaoxi ^[4]; Zuo, Zhiyi ^[5]; Tang, Yamei ^[1]

---

1. Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou (China)
2. Department of Radiation Oncology, Cancer Center of Sun Yat-sen University, Guangzhou (China)
3. Department of Neurology, Guangzhou Brain Hospital, Guangzhou (China)
4. Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou (China)
5. Department of Anesthesiology, University of Virginia, Charlottesville (United States)

Studies have shown that addition of bevacizumab to corticosteroids improves outcome against radiation-induced brain necrosis (RN). Here, we aimed to evaluate the effectiveness and safety of bevacizumab monotherapy on RN in nasopharyngeal carcinoma (NPC) patients.

• OSTI ID: 23073254
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 101; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BRAIN
CARCINOMAS
CORTICOSTEROIDS
NECROSIS
PATIENTS
SAFETY